Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus nivolumab plus placebo in recurrent or metastatic SCCHN
NL-OMON47328Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Nivolumab + ipilimumab with Nivolumab + ipilimumab placebo (2 arms). Primary endpoints: Objective response rate and Duration of response. Started Dec 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON47328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47328.